ArticleUnited European gastroenterology journal2020
Discriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study.
Article in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Butyrate Formulation and a Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms
A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- A systematic and critical review of measurement scales for evaluating gastrointestinal symptoms during exercise.Journal of the International Society of Sports Nutrition · 2026Pooled it
- Evaluation of safety and efficacy of the combination of mebeverine and sulpiride in treatment of patients with functional gastrointestinal disorders: A prospective cohort.The Journal of international medical research · 2026Trial
- The Usefulness of the Low-FODMAP Diet with Limited Tryptophan Intake in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome.Nutrients · 2023Trial
- Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.BMC gastroenterology · 2021Trial
- Association between increased microbiota awareness and lower gastrointestinal symptom severity: a cross-sectional analysis.BMC gastroenterology · 2026Article
- Dietary index for gut microbiota (DI-GM) and irritable bowel syndrome: a case-control study.Scientific reports · 2026Article
- Assessment of the Effectiveness of Pharmaceutical Advice in Selected Digestive Disorders: Perspectives of Patients and Pharmacists as Part of a Pilot "Minor Ailments" Service.Diseases (Basel, Switzerland) · 2026Article
- The Norwegian Microbiota Study in Anorexia Nervosa (NORMA): Integrating a clinical trial with preclinical experiments-A study protocol.PloS one · 2026Article
- Outcome measures for irritable bowel syndrome: a scoping review.BMC medical research methodology · 2025Article
- Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study.Nutrients · 2025Article
- Periodic Changes in the Gut Microbiome in Women with the Mixed Type of Irritable Bowel Syndrome.Biomedicines · 2025Article
- Deep brain stimulation for obsessive compulsive disorder leads to symptom changes of comorbid irritable bowel syndrome.Frontiers in psychiatry · 2025Article
- A1 protein free milk benefits mood and subjective cognition in free-living Australian adults: a pragmatic, exploratory, open label randomised controlled trial.Frontiers in nutrition · 2025Article
- Gastrointestinal symptoms among recreational long distance runners in China: prevalence, severity, and contributing factors.Frontiers in nutrition · 2025Article
- An Exploratory Study Investigating the Prevalence of Gastrointestinal Symptoms in Collegiate Division I American Football Athletes.International journal of environmental research and public health · 2023Article
- Changes in Tryptophan Metabolism on Serotonin and Kynurenine Pathways in Patients with Irritable Bowel Syndrome.Nutrients · 2023Article
- A Reduced Tryptophan Diet in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Improves Their Abdominal Symptoms and Their Quality of Life through Reduction of Serotonin Levels and Its Urinary Metabolites.International journal of molecular sciences · 2022Article
- Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth.Nutrients · 2022Article
- Review article: exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2022Review
- Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson's Disease Cohort.Parkinson's disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) is a 13-item measure of IBS symptom severity. The scale has been used in several studies, but its psychometric properties have been insufficiently investigated and population-based data are not available.
objectiveThe objective of this article is to establish the factor structure and discriminant and convergent validity of the GSRS-IBS.
methodsThe study was based on a Swedish population sample (the Popcol study), of which 1158 randomly selected participants provided data on the GSRS-IBS. We used confirmatory factor analysis (CFA) and compared total and subscales scores in different groups, including IBS diagnostic status, treatment-seeking behavior, and predominant bowel habits. The GSRS-IBS scores were also correlated with quality of life indexes.
resultsThe sample included 164 participants with a confirmed Rome III IBS diagnosis and 994 participants without the disease. The CFA confirmed the subscales with one exception, in which the incomplete bowel-emptying item belonged to the constipation subscale rather than the diarrhea subscale. The GSRS-IBS total score and subscales were associated with diagnostic status, treatment-seeking behavior, and quality of life dimensions. The relevant subscales scores also differed between the diarrhea- and constipation-predominant subtypes of IBS.
conclusionThe GSRS-IBS total score and subscales have high discriminant and convergent validity. The CFA confirmed the overall validity of the subscales but suggest that a sense of incomplete emptying belongs to the constipation rather than the diarrhea symptom cluster. We conclude that the GSRS-IBS is an excellent measure of IBS symptom severity in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.